ATNX Athenex Inc.

Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer.

$3.75  -0.23 (-5.78%)
As of 07/23/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Drug Manufacturers—Specialty &
Index country:  USA
Country of incorporation:  USA
IPO date:  06/14/2017
Outstanding shares:  93,512,700
Average volume:  1,287,476
Market cap:   $372,180,546
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    04685N103
ISIN:        US04685N1037
Sedol:      BF04FC3
Valuation   (See tab for details)
PE ratio:   -2.31
PB ratio:   2.22
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy